反应详情

To a solution of 4-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methylamino)-2-chloropyrimidine-5-carboxylic acid (503 mg, 1.41 mmol) and HOBt monohydrate (280 mg, 1.83 mmol) in DMF (8 mL), EDC (352 mg, 1.83 mmol) was added. After 1 h of stirring, conc. NH4OH (0.400 mL, ca. 5.60 mmol) was added. The mixture was stirred at room temperature for 18 h. Water and EtOAc were added. The organic phase was separated, washed with 5% NaHCO3, dried over Na2SO4, concentrated in vacuo to give tert-butyl 3-((2-(1H-benzo[d][1,2,3]triazol-1-yloxy)-5-carbamoylpyrimidin-4-ylamino)methyl)pyrrolidine-1-carboxylate (472 mg).

1. stirringThe mixture was stirred at room temperature for 18 h
2. customThe organic phase was separated
3. washwashed with 5% NaHCO3
4. dry with materialdried over Na2SO4
5. concentrationconcentrated in vacuo